PCM
CBIO

Penserra Capital Management’s Crescent Biopharma CBIO Stock Holding History

Penserra Capital Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-4
Closed -$1K – 1060
2020
Q3 		$1K Buy
+4
New +$1.53K ﹤0.01% 922

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Penserra Capital Management's CBIO Position: Q4 2020 in Review

Penserra Capital Management sold out of Crescent Biopharma (CBIO) in Q4 2020, closing a stake of 4 shares — an estimated $1K sold.

Penserra Capital Management first reported a position in CBIO in Q3 2020 and held it in 1 quarter. The position peaked at $1K in Q3 2020. 89 funds tracked by Wall St. Rank hold CBIO as of Q4 2020.

  • Penserra Capital Management reported no remaining Crescent Biopharma position as of Q4 2020 after selling out during the quarter.
  • Penserra Capital Management sold 4 Crescent Biopharma shares in Q4 2020, an estimated $1K.
  • Penserra Capital Management first reported a position in Crescent Biopharma in Q3 2020 and held it in 1 quarter.
  • Penserra Capital Management's Crescent Biopharma position peaked at $1K in Q3 2020.
  • 89 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2020.

Based on Penserra Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.